These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

189 related items for PubMed ID: 11455061

  • 21. Interleukin-6 fused to an anti-idiotype antibody in a vaccine increases the specific humoral immune response against CA125+ (MUC-16) ovarian cancer.
    Reinartz S, Hombach A, Köhler S, Schlebusch H, Wallwiener D, Abken H, Wagner U.
    Cancer Res; 2003 Jun 15; 63(12):3234-40. PubMed ID: 12810653
    [Abstract] [Full Text] [Related]

  • 22. Bispecific anti-HER2 and CD16 single-chain antibody production prolongs the use of stem cell-like cell transplantation against HER2-overexpressing cancer.
    Kasuya K, Shimazu M, Suzuki M, Itoi T, Aoki T, Tsuchida A.
    Int J Mol Med; 2010 Feb 15; 25(2):209-15. PubMed ID: 20043129
    [Abstract] [Full Text] [Related]

  • 23. Long-term immunity elicited by antibody-cytokine fusion proteins protects against sequential challenge with murine mammary and colon malignancies.
    Helguera G, Rodríguez JA, Daniels TR, Penichet ML.
    Cancer Immunol Immunother; 2007 Sep 15; 56(9):1507-12. PubMed ID: 17310381
    [Abstract] [Full Text] [Related]

  • 24. AHNP-streptavidin: a tetrameric bacterially produced antibody surrogate fusion protein against p185her2/neu.
    Masuda K, Richter M, Song X, Berezov A, Masuda K, Murali R, Greene MI, Zhang H.
    Oncogene; 2006 Dec 14; 25(59):7740-6. PubMed ID: 16785990
    [Abstract] [Full Text] [Related]

  • 25. Enhancement of antitumor immune response by targeted interleukin-12 electrogene transfer through antiHER2 single-chain antibody in a murine bladder tumor model.
    Tsai YS, Shiau AL, Chen YF, Tsai HT, Lee HL, Tzai TS, Wu CL.
    Vaccine; 2009 Aug 27; 27(39):5383-92. PubMed ID: 19596413
    [Abstract] [Full Text] [Related]

  • 26. Efficient growth inhibition of ErbB2-overexpressing tumor cells by anti-ErbB2 ScFv-Fc-IL-2 fusion protein in vitro and in vivo.
    Shi M, Zhang L, Gu HT, Jiang FQ, Qian L, Yu M, Chen GJ, Luo Q, Shen BF, Guo N.
    Acta Pharmacol Sin; 2007 Oct 27; 28(10):1611-20. PubMed ID: 17883948
    [Abstract] [Full Text] [Related]

  • 27. A single vaccination with polyomavirus VP1/VP2Her2 virus-like particles prevents outgrowth of HER-2/neu-expressing tumors.
    Tegerstedt K, Lindencrona JA, Curcio C, Andreasson K, Tullus C, Forni G, Dalianis T, Kiessling R, Ramqvist T.
    Cancer Res; 2005 Jul 01; 65(13):5953-7. PubMed ID: 15994974
    [Abstract] [Full Text] [Related]

  • 28. Construction of a chimeric antibody with therapeutic potential for cancers which overexpress c-erbB-2.
    Liu HL, Parkes DL, Langton BC, Xuan JA, Longhi M, Elliger SS, Chao LA, McGrogan MP, Brandis JW, Shawver LK.
    Biochem Biophys Res Commun; 1995 Jun 26; 211(3):792-803. PubMed ID: 7598708
    [Abstract] [Full Text] [Related]

  • 29. Recombinant vesicular stomatitis virus targeted to Her2/neu combined with anti-CTLA4 antibody eliminates implanted mammary tumors.
    Gao Y, Whitaker-Dowling P, Griffin JA, Barmada MA, Bergman I.
    Cancer Gene Ther; 2009 Jan 26; 16(1):44-52. PubMed ID: 18654610
    [Abstract] [Full Text] [Related]

  • 30. Targeted delivery of an antibody-mutant human endostatin fusion protein results in enhanced antitumor efficacy.
    Shin SU, Cho HM, Merchan J, Zhang J, Kovacs K, Jing Y, Ramakrishnan S, Rosenblatt JD.
    Mol Cancer Ther; 2011 Apr 26; 10(4):603-14. PubMed ID: 21393427
    [Abstract] [Full Text] [Related]

  • 31. Protein vaccination with the HER2/neu extracellular domain plus anti-HER2/neu antibody-cytokine fusion proteins induces a protective anti-HER2/neu immune response in mice.
    Dela Cruz JS, Lau SY, Ramirez EM, De Giovanni C, Forni G, Morrison SL, Penichet ML.
    Vaccine; 2003 Mar 28; 21(13-14):1317-26. PubMed ID: 12615426
    [Abstract] [Full Text] [Related]

  • 32. Blockade of her2/neu decreases VEGF expression but does not alter HIF-1 distribution in experimental Wilms tumor.
    Yokoi A, McCrudden KW, Huang J, Kim ES, Soffer SZ, Frischer JS, Serur A, New T, Yuan J, Mansukhani M, O'Toole K, Yamashiro DJ, Kandel JJ.
    Oncol Rep; 2003 Mar 28; 10(5):1271-4. PubMed ID: 12883692
    [Abstract] [Full Text] [Related]

  • 33. Combination of adoptive immunotherapy with Herceptin for patients with HER2-expressing breast cancer.
    Kubo M, Morisaki T, Kuroki H, Tasaki A, Yamanaka N, Matsumoto K, Nakamura K, Onishi H, Baba E, Katano M.
    Anticancer Res; 2003 Mar 28; 23(6a):4443-9. PubMed ID: 14666732
    [Abstract] [Full Text] [Related]

  • 34. A RANTES-antibody fusion protein retains antigen specificity and chemokine function.
    Challita-Eid PM, Abboud CN, Morrison SL, Penichet ML, Rosell KE, Poles T, Hilchey SP, Planelles V, Rosenblatt JD.
    J Immunol; 1998 Oct 01; 161(7):3729-36. PubMed ID: 9759898
    [Abstract] [Full Text] [Related]

  • 35. Chimeric (mouse/human) anti-colon cancer antibody c30.6 inhibits the growth of human colorectal cancer xenografts in scid/scid mice.
    Mount PF, Sutton VR, Li W, Burgess J, McKEnzie IF, Pietersz GA, Trapani JA.
    Cancer Res; 1994 Dec 01; 54(23):6160-6. PubMed ID: 7954462
    [Abstract] [Full Text] [Related]

  • 36. A novel approach to tumor suppression with microencapsulated recombinant cells.
    Cirone P, Bourgeois JM, Austin RC, Chang PL.
    Hum Gene Ther; 2002 Jul 01; 13(10):1157-66. PubMed ID: 12133269
    [Abstract] [Full Text] [Related]

  • 37. [Breast cancer].
    Tokuda Y, Saito Y, Suzuki Y, Ohta M, Tajima T.
    Nihon Rinsho; 2002 Mar 01; 60(3):563-9. PubMed ID: 11904974
    [Abstract] [Full Text] [Related]

  • 38. Biological properties of a human compact anti-ErbB2 antibody.
    De Lorenzo C, Cozzolino R, Carpentieri A, Pucci P, Laccetti P, D'Alessio G.
    Carcinogenesis; 2005 Nov 01; 26(11):1890-5. PubMed ID: 15930029
    [Abstract] [Full Text] [Related]

  • 39. [Human recombinant anti-HER2 monoclonal antibody--a new targeted treatment in breast cancer].
    Dank M.
    Orv Hetil; 2001 Nov 18; 142(46):2563-8. PubMed ID: 11770175
    [Abstract] [Full Text] [Related]

  • 40. In vivo examination of (188)Re(I)-tricarbonyl-labeled trastuzumab to target HER2-overexpressing breast cancer.
    Chen KT, Lee TW, Lo JM.
    Nucl Med Biol; 2009 May 18; 36(4):355-61. PubMed ID: 19423002
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.